Myasthenia gravis patients with low plasma IL-6 and IFN-γ benefit from etanercept treatment

Erdem Tüzün, Matthew N. Meriggioli, Julie Rowin, Huan Yang, Premkumar Christadoss

Research output: Contribution to journalArticle

47 Citations (Scopus)

Abstract

Steroid-dependent myasthenia gravis patients improved following treatment with etanercept (recombinant human TNF receptor:Fc) in a prospective pilot trial. While the plasma anti-acetylcholine receptor antibody levels remained unaffected, etanercept treatment increased plasma levels of C3, circulating immune complexes, IL-10 and IFN-γ. There was a direct correlation between plasma IL-6, TNF-α and IFN-γ levels and the post-treatment clinical scores of patients. Moreover, patients with lower pre-treatment plasma IL-6 and IFN-γ levels attained better clinical improvement following etanercept treatment.

Original languageEnglish (US)
Pages (from-to)261-268
Number of pages8
JournalJournal of Autoimmunity
Volume24
Issue number3
DOIs
StatePublished - May 2005

Fingerprint

Myasthenia Gravis
Interleukin-6
Therapeutics
Tumor Necrosis Factor Receptors
Cholinergic Receptors
Antigen-Antibody Complex
Interleukin-10
Steroids
Etanercept
Antibodies

Keywords

  • Autoimmunity
  • Etanercept
  • Interferon-γ
  • Interleukin-6
  • Myasthenia gravis

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy

Cite this

Myasthenia gravis patients with low plasma IL-6 and IFN-γ benefit from etanercept treatment. / Tüzün, Erdem; Meriggioli, Matthew N.; Rowin, Julie; Yang, Huan; Christadoss, Premkumar.

In: Journal of Autoimmunity, Vol. 24, No. 3, 05.2005, p. 261-268.

Research output: Contribution to journalArticle

Tüzün, Erdem ; Meriggioli, Matthew N. ; Rowin, Julie ; Yang, Huan ; Christadoss, Premkumar. / Myasthenia gravis patients with low plasma IL-6 and IFN-γ benefit from etanercept treatment. In: Journal of Autoimmunity. 2005 ; Vol. 24, No. 3. pp. 261-268.
@article{8760bae07f674d11b88da64c40262e71,
title = "Myasthenia gravis patients with low plasma IL-6 and IFN-γ benefit from etanercept treatment",
abstract = "Steroid-dependent myasthenia gravis patients improved following treatment with etanercept (recombinant human TNF receptor:Fc) in a prospective pilot trial. While the plasma anti-acetylcholine receptor antibody levels remained unaffected, etanercept treatment increased plasma levels of C3, circulating immune complexes, IL-10 and IFN-γ. There was a direct correlation between plasma IL-6, TNF-α and IFN-γ levels and the post-treatment clinical scores of patients. Moreover, patients with lower pre-treatment plasma IL-6 and IFN-γ levels attained better clinical improvement following etanercept treatment.",
keywords = "Autoimmunity, Etanercept, Interferon-γ, Interleukin-6, Myasthenia gravis",
author = "Erdem T{\"u}z{\"u}n and Meriggioli, {Matthew N.} and Julie Rowin and Huan Yang and Premkumar Christadoss",
year = "2005",
month = "5",
doi = "10.1016/j.jaut.2005.01.013",
language = "English (US)",
volume = "24",
pages = "261--268",
journal = "Journal of Autoimmunity",
issn = "0896-8411",
publisher = "Academic Press Inc.",
number = "3",

}

TY - JOUR

T1 - Myasthenia gravis patients with low plasma IL-6 and IFN-γ benefit from etanercept treatment

AU - Tüzün, Erdem

AU - Meriggioli, Matthew N.

AU - Rowin, Julie

AU - Yang, Huan

AU - Christadoss, Premkumar

PY - 2005/5

Y1 - 2005/5

N2 - Steroid-dependent myasthenia gravis patients improved following treatment with etanercept (recombinant human TNF receptor:Fc) in a prospective pilot trial. While the plasma anti-acetylcholine receptor antibody levels remained unaffected, etanercept treatment increased plasma levels of C3, circulating immune complexes, IL-10 and IFN-γ. There was a direct correlation between plasma IL-6, TNF-α and IFN-γ levels and the post-treatment clinical scores of patients. Moreover, patients with lower pre-treatment plasma IL-6 and IFN-γ levels attained better clinical improvement following etanercept treatment.

AB - Steroid-dependent myasthenia gravis patients improved following treatment with etanercept (recombinant human TNF receptor:Fc) in a prospective pilot trial. While the plasma anti-acetylcholine receptor antibody levels remained unaffected, etanercept treatment increased plasma levels of C3, circulating immune complexes, IL-10 and IFN-γ. There was a direct correlation between plasma IL-6, TNF-α and IFN-γ levels and the post-treatment clinical scores of patients. Moreover, patients with lower pre-treatment plasma IL-6 and IFN-γ levels attained better clinical improvement following etanercept treatment.

KW - Autoimmunity

KW - Etanercept

KW - Interferon-γ

KW - Interleukin-6

KW - Myasthenia gravis

UR - http://www.scopus.com/inward/record.url?scp=17444370887&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=17444370887&partnerID=8YFLogxK

U2 - 10.1016/j.jaut.2005.01.013

DO - 10.1016/j.jaut.2005.01.013

M3 - Article

C2 - 15848049

AN - SCOPUS:17444370887

VL - 24

SP - 261

EP - 268

JO - Journal of Autoimmunity

JF - Journal of Autoimmunity

SN - 0896-8411

IS - 3

ER -